OLIVA, STEFANIA
 Distribuzione geografica
Continente #
NA - Nord America 2.162
EU - Europa 1.722
AS - Asia 888
OC - Oceania 71
SA - Sud America 54
AF - Africa 16
Totale 4.913
Nazione #
US - Stati Uniti d'America 2.055
IT - Italia 838
CN - Cina 437
SE - Svezia 148
DE - Germania 135
JP - Giappone 133
IE - Irlanda 113
GB - Regno Unito 110
KR - Corea 86
CA - Canada 81
IN - India 76
FR - Francia 68
AU - Australia 63
VN - Vietnam 49
NL - Olanda 40
ES - Italia 39
FI - Finlandia 30
UA - Ucraina 30
CH - Svizzera 29
BE - Belgio 28
SG - Singapore 26
BR - Brasile 25
MX - Messico 23
TR - Turchia 20
PL - Polonia 18
CO - Colombia 17
AT - Austria 14
GR - Grecia 14
PT - Portogallo 13
DK - Danimarca 12
RU - Federazione Russa 12
HK - Hong Kong 10
HU - Ungheria 10
PK - Pakistan 10
TH - Thailandia 9
NZ - Nuova Zelanda 8
CL - Cile 7
TW - Taiwan 7
ID - Indonesia 6
IR - Iran 6
NO - Norvegia 5
ZA - Sudafrica 5
AR - Argentina 4
EG - Egitto 4
HR - Croazia 4
IL - Israele 4
RO - Romania 4
SN - Senegal 4
DZ - Algeria 3
SK - Slovacchia (Repubblica Slovacca) 3
BG - Bulgaria 2
CZ - Repubblica Ceca 2
PH - Filippine 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
CU - Cuba 1
EC - Ecuador 1
GT - Guatemala 1
KZ - Kazakistan 1
MN - Mongolia 1
MY - Malesia 1
PA - Panama 1
RS - Serbia 1
Totale 4.913
Città #
Florence 282
Chandler 169
Ashburn 162
Fairfield 133
Beijing 114
Dublin 110
Torino 104
Wilmington 87
Houston 84
Woodbridge 82
Redwood City 76
Duncan 70
Nyköping 70
Seattle 65
Cambridge 52
Turin 48
Tokyo 47
Dearborn 40
Ottawa 40
Ann Arbor 38
Shanghai 37
Medford 33
Hangzhou 30
Raritan 28
Princeton 27
Dong Ket 25
San Francesco 24
Guangzhou 23
Perth 23
Villeurbanne 22
Jacksonville 21
London 19
New York 19
Milan 17
Nanjing 17
Rochester 16
Seoul 16
Campi Bisenzio 15
Changchun 15
Loma Linda 14
Wuhan 14
Noto 13
Rome 13
Sydney 13
Boston 12
Fremont 12
Nanchang 12
Pisa 12
Brussels 11
Singapore 11
Vienna 11
Baotou 10
Chengdu 10
Xian 10
Padova 9
Pune 9
San Diego 9
Budapest 8
Changsha 8
San Mateo 8
São Paulo 8
Udine 8
Zhengzhou 8
Chennai 7
Hebei 7
Hyderabad 7
Islamabad 7
Medellín 7
Ontario 7
Paris 7
Santiago 7
Toronto 7
Bogotá 6
Hefei 6
Oxford 6
Taipei 6
Tianjin 6
Warsaw 6
Washington 6
Barcelona 5
Chicago 5
Detroit 5
Düsseldorf 5
Forcoli 5
Fuzhou 5
Helsinki 5
Madrid 5
Munich 5
Phoenix 5
Tacoma 5
Venaria 5
Watertown 5
Altfraunhofen 4
Atlanta 4
Bangalore 4
Bern 4
Bologna 4
Brisbane 4
Charlotte 4
Cleveland 4
Totale 2.755
Nome #
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial 1.446
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 765
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group 381
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 217
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results 216
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 178
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 173
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis 164
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis 151
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma 142
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 129
Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma 108
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 108
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents 90
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 89
Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies 79
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 77
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma 71
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives 65
Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved? 59
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 58
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma 58
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set 54
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 50
Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time? 46
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 44
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials 25
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 23
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 7
Predictors of Unsustained Minimal Residual Disease Negativity in Multiple Myeloma (MM) Patients 4
Totale 5.077
Categoria #
all - tutte 10.015
article - articoli 0
book - libri 0
conference - conferenze 330
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.345


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019139 0 0 0 0 0 0 0 0 0 43 56 40
2019/2020768 43 33 37 88 57 63 48 47 129 91 85 47
2020/2021784 51 42 61 47 99 65 73 79 57 54 58 98
2021/2022856 55 61 37 102 56 43 39 57 39 75 149 143
2022/2023799 53 107 57 92 52 134 45 54 77 31 59 38
2023/2024470 55 76 38 60 37 86 55 39 3 21 0 0
Totale 5.077